Notice ID: 29f37de6852742ffa8300a115aaa4007Award NoticeAwardedArchived
A--Cybersecurity of Novel Technology Implementations
Awarded on August 27, 2026. Full description on SAM.gov.
Awarded tounder 31310026C0015 (source: SAM.gov award notice)• $250.0K
Overview
- Posted
- August 27, 2026
- Notice type
- Award Notice
- NAICS
- 541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Agency
- Nuclear Regulatory Commission
Notice details
- Office
- NUCLEAR REGULATORY COMMISSION
- PSC
- AJ12: R&D- GENERAL SCIENCE/TECHNOLOGY: PHYSICAL SCIENCES (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
- Award date
- Aug 27, 2026
- Award amount (SAM.gov award notice)
- $250.0K
Identifiers
- Solicitation number
- 31310026R0012
- Notice ID
- 29f37de6852742ffa8300a115aaa4007
- Award number (PIID)
- 31310026C0015
Description
Cybersecurity of Novel Technology Implementations in Operating and New/Advanced Reactors – Artificial Intelligence and Machine Learning
Award Overview
Award Number
31310026C0015
Award Amount (SAM.gov award notice)
$250.0K
Award Date
Aug 27, 2026
Awardee
Awardee UEI
PWVLYL3MVHL5
Awardee CAGE Code
547M4
Awardee Address
3463 MAGIC DR, STE 220, San Antonio, TX 78229, UNITED STATES
Original Solicitation
Notice ID: 29f37de6852742ffa8300a115aaa4007
Posted Date: Aug 27, 2026
Original Response Deadline: Not specified
Contacts
Contracting Officer
Primary Contact
Documents
Links (1)
- Click here to see more information about this opportunity on FedConnectwww.fedconnect.netPosted
Lifecycle
- 2Version 2SolicitationArchived
A--Cybersecurity of Novel Technology Implementations
- 5Version 5Award NoticeArchivedCurrent
Type changed from Solicitation to Award Notice
A--Cybersecurity of Novel Technology Implementations
Other notices for this solicitation
- SolicitationRelated noticeMay 5, 2026
Cybersecurity of Novel Technology Implementations
- SolicitationRelated noticeMay 21, 2026
A--Cybersecurity of Novel Technology Implementations
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Randomized Controlled Trial of a Novel Clinical Decision Support Tool for Individualized Exercise Recommendations in Breast Cancer Survivors. | - | Pre-Solicitation | 11/25/2026 |
This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections. This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product. The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance). The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022. NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date). Amendment 0001 – removed alternate point of contact information under “Contract Information” on SAM.gov Amendment 0002 – revised proposal due date from: 12:00pm eastern, Friday, 23 Oct 2026 to: 12:00pm eastern Friday, 06 Nov 2026 Amendment 0003 – revised proposal due date from: 12:00pm eastern Friday, 06 Nov 2026 to: 12:00pm eastern Friday, 20 Nov 2026 | - | Solicitation | 11/20/2026 |
The Defense Health Agency Contracting Activity, on behalf of Portfolio Acquisition Executive for Medical Products, Warfighter Protection and Acute Care Project Management Office, intends to issue a contract modification on a sole-source basis with Westat Inc. 1600 Research Blvd. Rockville, MD 20850. This modification will enable Westat Inc. to modify the current clinical trial design to comply with FDA recommendations and to conduct the Good Clinical Practices (GCP) compliant clinical trial in accordance with U.S. Food and Drug Administration’s requirements for EZPLAZ™ approval. | - | Market Research | 11/16/2026 |
This is a Small Business Sources Sought (SBSS) Notice for Research and Development (R&D). This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of qualified small businesses under the size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. The anticipated North American Industry Classification System (NAICS) code is 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and the small business size standard for such requirements is 1,000 employees or less, including applicable affiliates. This SBSS notice is for market research and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. The purpose of this synopsis is to identify small business organizations with requisite qualifications to provide the services stated herein. Based on capability statements received in response to this Sources Sought Announcement, this acquisition may be solicited as a small business set-aside. All small business organizations (SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB) are encouraged to respond to this notice. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. | - | Market Research | 11/23/2026 |
INTRODUCTION: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens. NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (https://aspr.hhs.gov/PHEMCE/2024-PHEMCE-SIP/Pages/default.aspx), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html). In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation. An offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of this BAA Solicitation, instructions regarding the proposal submission, and a description of the evaluation and award process. Please note, due to the competitive nature of the BAA Solicitation, the NIAID is unable to offer advice or feedback regarding an offeror’s specific technical approach. Offerors should exercise their professional judgment when compiling their proposals in line with the requirements and specifications of the BAA Solicitation. Research Area 001 - Vaccine Candidates: The objective is to develop vaccine candidates through an early phase clinical trial that use a needle free (i.e., alternative to classical needle and syringe, see below for description) route of delivery to protect against infections caused by viral pathogens that include but are not limited to respiratory and vector borne viruses. The scope of this vaccine research area includes the preclinical development of a needle free vaccine candidate, IND enabling studies, limited process development, Good Manufacturing Practice (GMP) compliant manufacturing, regulatory submissions to the U.S. Food and Drug Administration (FDA) and conduct of a Phase 1 or early Phase 2 clinical trial. The scope of work must include a clinical trial. Offerors must propose a single vaccine candidate for protection against a specific viral pathogen. The vaccine candidate may provide a breadth of protection against other viral strains or viruses. A strong justification is required to support (1) the proposed vaccine antigen and platform for the disease indication, (2) the use of a clinically relevant adjuvant (if needed), and (3) a clinically relevant needle free route of delivery. Research Area 002 - Therapeutic Candidates: The objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Infectious diseases caused by the following viruses, bacteria and fungi pathogens are targeted: Viral hemorrhagic fever viruses (e.g., EBOV, SUDV, MARV, LASV, hantavirus) https://www.cdc.gov/viral-hemorrhagic-fevers/about/index.html Encephalitic paramyxoviruses (e.g. hendra virus, nipah virus) Picornaviruses (broad spectrum approaches that include EV68, EV70 and coxsackie virus) At least two of the following (i.e., addressed with a broad spectrum antimicrobial): susceptible and carbapenem-resistant Enterobacteriaceae (CRE), susceptible and multidrug resistant (MDR) Pseudomonas aeruginosa, and susceptible and Carbapenem-resistant Acinetobacter (CRAB), with potential to improve patient outcomes in the clinic; Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales Adjunct medical interventions to support or enhance effectiveness of antimicrobial agents to address underlying pathology that is not resolved after clearance of pathogens, may be considered. Important notice to Offerors: For this Research Area, “therapeutic” activity means curing disease by eliminating or substantially reducing infective pathogens by administering antimicrobial pharmaceutical agents, with or without a host-directed therapy. Additionally, proposed therapeutic products should consider the impact on a healthy microbiome. Preventative treatments are not included in the scope of this Research Area. A therapeutic candidate refers to an advanced lead series, preclinical candidates, or a clinical candidate, that is a new chemical entity. This includes small molecules, natural products, nucleosides, or peptides of </= 40 amino acids, monoclonal antibodies, nanobodies, nanobody conjugate/fusion products, microbiome-based therapeutics or bacteriophages. Research Area 002 will support lead optimization, pre-clinical Investigational New Drug (IND) enabling studies, and Phase 1 clinical trials (or proof of concept Phase 2 clinical trials) of lead candidates with demonstrated therapeutic activities. This includes support for traditional, novel (e.g., small molecules) and non-traditional (e.g., including but not limited to phage, and host-directed) therapeutics for infectious diseases where patients lack effective interventions, as well as therapeutics that promote host-mediated resolution of disease. The scope of support differs depending on the developmental stage of the project being proposed, which is further discussed in the BAA Solicitation. Research Area 003 - In Vitro Diagnostics The objective of Research Area 003 is to develop innovative, technology platforms that will speed detection and identification of infectious viruses covering a broad panel of virus families, including viruses causing acute infections as well as those causing chronic infections. Technology platform innovation to achieve faster actionable sequencing results (approaching 2 hr) direct from primary clinical specimens, as well as more accessible workflow and configuration (i.e., point-of-care) are preferred. Furthermore, full sample-to-answer platform solutions are preferred. The system should accept specimen volumes from 0.5 to 5 milliliters (mL). The system should include nearly full automation (little or no hands-on activity after specimen has been loaded into system). Sample preparation components of the system should yield sufficient analyte recovery from a starting titer of 10-100 genomic copies per mL of biofluid for downstream analysis, including detection, identification, and characterization of the nucleic acid material. Innovations during platform development might include, for example: Automated sample prep for high recovery from low pathogen load. Faster specimen-to-answer for total test time <2 hours. Broad viral pathogen detection capability, covering one or more members of the priority pathogen families (see below). Targeted, or even untargeted pathogen detection and identification via long-read sequencing or other detection methods. Multiple specimen throughput per run for reduced cost. Analytical sensitivity approaching 5-50 genome copies per mL of starting biofluid. Assay reconfigurability to respond rapidly to a novel pathogen in days or weeks rather than months (i.e., agnostic diagnostic solution). Priority Pathogens The diagnostic test system must detect analytes from at least one, and preferably several, of the following agents and markers: Arenaviridae (e.g., Lassa virus) Phenuviridae (e.g., Rift Valley fever virus) Peribunyayviridae (e.g., Oropouche virus) Hantaviridae (e.g., Hantavirus) Nairoviridae (e.g., Crimean Congo Hemorrhagic fever virus) Filoviridae (e.g., Sudan virus, Ebola virus, Marburg virus) Flaviviridae (e.g., Hepatitis C virus, West Nile Virus) Paramyxoviridae (e.g., Nipah virus) Togaviridae (e.g., Chikungunya virus) Picornaviridae (e.g., Enterovirus) PROPOSAL SUBMISSION: Proposals Due Date and Time – December 8, 2026, 3:00 PM Eastern Time For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by any other method is not permitted. For directions on using eCPS, go to the website: https://ecps.nih.gov and thenclick on "How to Submit." | - | Solicitation | 12/08/2026 |
Additional Details
Solicitation Number
31310026R0012
Archive Date
Sep 11, 2026
Office Address
ROCKVILLE, MD, 20855